TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06823167: A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies

Sponsor: Immunome, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 190 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$6,974,352

Rescue Site Savings

+$4,618,152

Unlock Full NCT06823167 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06823167 Rescue Dossier →